CJC-1295 won't be found on pharmacy shelves in Dynów or virtually any local market — it's a research compound distributed through a dedicated online market. This online-only market structure is a genuine benefit for researchers — top vendors differentiate through analytical documentation in ways no local retailer can match. The core quality markers for CJC-1295 are HPLC purity ≥98%, molecular identity confirmed by mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. The sections below cover what Dynów researchers need to know about sourcing, verifying, and handling CJC-1295 for scientific research use.
Understanding CJC-1295 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Dynów researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Vetting CJC-1295 vendors requires starting from the COA: access the batch-specific certificate before placing an order, not after. A COA for CJC-1295 should include: HPLC purity percentage with the actual chromatogram data, mass spectrometry data verifying the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. Negative indicators in CJC-1295 vendor evaluation: prices more than 30-40% below standard market rates, vague sourcing information, no community presence, and COAs that do not include endotoxin results. Bacteriostatic water is the correct reconstitution medium for CJC-1295 — it contains 0.9% benzyl alcohol that prevents microbial contamination and extends reconstituted shelf life to 30 days refrigerated.
Order CJC-1295 — ships to Dynów
COA-verified · International tracking · Research grade
CJC-1295 is available for research use only and is not approved for human therapeutic use by the FDA or equivalent agencies worldwide — all information here is for educational purposes only. Proper handling of CJC-1295 requires careful sterile procedure — alcohol-swabbed septum, fresh needles, clean working environment — and consistent cold chain handling. Bacterial endotoxin contamination is the greatest safety hazard unique to this class of compound — verify endotoxin testing is present in the lot-matched certificate before any injectable research application. PubMed and bioRxiv are the primary literature resources for CJC-1295 research; favour indexed journal publications over preprints over conference abstracts or single case observations.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
